Drug Profile
TolerMab TRX 4 - TolerRx
Alternative Names: TolerMab anti-CD3 monoclonal antibody - TolerRx; TolerMab TRX4; TRX 4 - TolerMab - TolerRxLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator TolerRx
- Class Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Type 1 diabetes mellitus
Most Recent Events
- 01 Sep 2005 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 01 Sep 2005 Discontinued - Preclinical for Type-1-diabetes-mellitus in USA (unspecified route)
- 05 Jul 2003 Preclinical trials in Autoimmune disorders in USA (unspecified route)